Provided by Tiger Fintech (Singapore) Pte. Ltd.

Axsome Therapeutics

103.00
-1.4600-1.40%
Post-market: 103.000.00000.00%17:54 EDT
Volume:688.59K
Turnover:71.02M
Market Cap:5.02B
PE:-17.18
High:104.17
Open:103.55
Low:101.58
Close:104.46
Loading ...

Top Analyst Reports for Apple, Philip Morris & Sony

Zacks
·
18 Apr

Axsome (AXSM) Moves 4.2% Higher: Will This Strength Last?

Zacks
·
10 Apr

Top Research Reports for Verizon, The Southern Co. & Blackstone

Zacks
·
08 Apr

Axsome Therapeutics Initiated at Buy by Jefferies

Dow Jones
·
07 Apr

Axsome Therapeutics: Promising CNS Pipeline and Growth Potential Justify Buy Rating

TIPRANKS
·
07 Apr

Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer’s Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting

GlobeNewswire
·
04 Apr

Axsome Therapeutics Price Target Maintained With a $200.00/Share by HC Wainwright & Co.

Dow Jones
·
03 Apr

RBC Trims Price Target on Axsome Therapeutics to $190 From $192, Keeps Outperform Rating

MT Newswires Live
·
03 Apr

Biotech Stock Roundup: CORT Up on Study Data, Updates From AXSM, BMY, EXEL & More

Zacks
·
03 Apr

Alkermes Begins Idiopathic Hypersomnia Study on ALKS 2680

Zacks
·
02 Apr

Deutsche Bank Adjusts Axsome Therapeutics Price Target to $187 From $200, Maintains Buy Rating

MT Newswires Live
·
02 Apr

Axsome Therapeutics Inc. : Deutsche Bank Cuts Target Price to $187 From $200

THOMSON REUTERS
·
02 Apr

Why Shares of Axsome Therapeutics Slumped Today

Motley Fool
·
02 Apr

Axsome Therapeutics Shares Down 4.5% After Co's Depression Treatment Fails to Meet Main Goal of Late-Stage Study

THOMSON REUTERS
·
01 Apr

Axsome Therapeutics Price Target Maintained With a $153.00/Share by Needham

Dow Jones
·
01 Apr

BUZZ-Axsome falls on depression drug's trial setback

Reuters
·
01 Apr

Axsome Therapeutics Shares Down 2.5% Premarket After Co's Depression Treatment Fails to Meet Main Goal of Late-Stage Study

THOMSON REUTERS
·
01 Apr

Axsome's depression treatment fails to meet main goal of late-stage study

Reuters
·
01 Apr

Axsome Therapeutics: in Overall Patient Population, Study Did Not Show Statistically Significant Change on Madrs Total Score VS Placebo

THOMSON REUTERS
·
01 Apr

Axsome Therapeutics Announces Topline Results of Paradigm Phase 3 Proof-of-Concept Trial of Solriamfetol in Major Depressive Disorder (Mdd) With and Without Excessive Daytime Sleepiness (Eds)

THOMSON REUTERS
·
01 Apr